Haeseong Park
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers 20
- HER2/EGFR in Cancer Research 18
- Pancreatic and Hepatic Oncology Research 10
- Colorectal Cancer Treatments and Studies 10
- Genetics top 2%
-
- Monoclonal and Polyclonal Antibodies Research 10
-
- Gastric Cancer Management and Outcomes 20
- Advanced Breast Cancer Therapies 12
- Lung Cancer Treatments and Mutations 9
- Cancer Research top 5%
- Co-authors
- Toshihiko DoiKenji TamuraShunji TakahashiJunji TsurutaniHiroji IwataMasahiro SugiharaCharles H. RedfernIan E. Krop
- Partner nations
- United StatesJapanSouth Korea
In The Last Decade
Haeseong Park
103 papers receiving 3.2k citations
Hit Papers
Peers
Comparison fields: 5 of 133
- Oncology 2.0k
- Genetics 375
- Radiology, Nuclear Medicine and Imaging 688
- Pulmonary and Respiratory Medicine 909
- Cancer Research 395
Countries citing papers authored by Haeseong Park
This map shows the geographic impact of Haeseong Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haeseong Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haeseong Park more than expected).
Fields of papers citing papers by Haeseong Park
This network shows the impact of papers produced by Haeseong Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haeseong Park. The network helps show where Haeseong Park may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Haeseong Park, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2026 | 0 | |
| 2 | 2024 | 2 | |
| 3 | 2023 | 7 | |
| 4 | Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 studybreakdown → | 2023 | 124 |
| 5 | 2023 | 1 | |
| 6 | 2023 | 7 | |
| 7 | 2023 | 10 | |
| 8 | 2022 | 24 | |
| 9 | 2022 | 1 | |
| 10 | 2022 | 1 | |
| 11 | 2021 | 12 | |
| 12 | 2021 | 20 | |
| 13 | 2020 | 76 | |
| 14 | 2020 | 5 | |
| 15 | 2019 | 12 | |
| 16 | Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 studybreakdown → | 2019 | 258 |
| 17 | 2019 | 162 | |
| 18 | 2013 | 14 | |
| 19 | Gender Differences Among Top Performing Elementary School Students in Mathematical Ability. | 1998 | 6 |
| 20 | Home language as a predictor of academic achievement: A comparative study of Mexican- and Asian-American youth. | 1994 | 28 |
About Haeseong Park
Haeseong Park is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics, having authored 111 papers that have together received 3.3k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (20 papers), Cancer Immunotherapy and Biomarkers (20 papers), HER2/EGFR in Cancer Research (18 papers), Advanced Breast Cancer Therapies (12 papers), Pancreatic and Hepatic Oncology Research (10 papers), Colorectal Cancer Treatments and Studies (10 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Lung Cancer Treatments and Mutations (9 papers). The work is most often cited by research in Oncology (2.0k citations), Genetics (375 citations) and Radiology, Nuclear Medicine and Imaging (688 citations). Haeseong Park has collaborated with scholars based in United States, Japan and South Korea. Frequent co-authors include Toshihiko Doi, Kenji Tamura, Shunji Takahashi, Junji Tsurutani, Hiroji Iwata, Masahiro Sugihara, Charles H. Redfern, Ian E. Krop, Shanu Modi and Javad Shahidi. Their work appears in journals such as JAMA, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.